These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 15320364)
1. The promise of targeted therapy: cancer drugs become more specific. Segota E; Bukowski RM Cleve Clin J Med; 2004 Jul; 71(7):551-60. PubMed ID: 15320364 [TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
3. [Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments]. Jochims C; Mazitschek U; Jäger D; Goldschmidt H Internist (Berl); 2006 Jun; 47(6):633-41. PubMed ID: 16767478 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic targets for the treatment of neurodegenerative diseases. Peedicayil J Clin Pharmacol Ther; 2016 May; 99(5):481. PubMed ID: 26669276 [No Abstract] [Full Text] [Related]
6. Molecularly targeted therapies for breast cancer. Hobday TJ; Perez EA Cancer Control; 2005 Apr; 12(2):73-81. PubMed ID: 15855890 [TBL] [Abstract][Full Text] [Related]
7. Nanotechnology applications in cancer. Nie S; Xing Y; Kim GJ; Simons JW Annu Rev Biomed Eng; 2007; 9():257-88. PubMed ID: 17439359 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. Rao AV; Schmader K Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665 [TBL] [Abstract][Full Text] [Related]
9. Recent development of molecular-targeted drugs in lung cancer. Saijo N; Kenmotsu H Intern Med; 2010; 49(18):1923-34. PubMed ID: 20847494 [TBL] [Abstract][Full Text] [Related]
10. Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer. Stuchbery R; Kurganovs NJ; McCoy PJ; Nelson CC; Hayes VM; Corcoran NM; Hovens CM Curr Cancer Drug Targets; 2015; 15(5):394-405. PubMed ID: 25882061 [TBL] [Abstract][Full Text] [Related]
11. Promising Targets for the Treatment of Neurodegenerative Diseases. Budd Haeberlein SL; Harris TJ Clin Pharmacol Ther; 2015 Nov; 98(5):492-501. PubMed ID: 26250447 [TBL] [Abstract][Full Text] [Related]
12. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Bodey B; Bodey B; Siegel SE; Kaiser HE Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379 [TBL] [Abstract][Full Text] [Related]
13. FDA panel recommends two new cancer drugs for approval. Finkelstein JB J Natl Cancer Inst; 2001 Feb; 93(3):175-6. PubMed ID: 11158184 [No Abstract] [Full Text] [Related]
14. Drug development for cancer chemoprevention: focus on molecular targets. Johnson KA; Brown PH Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505 [TBL] [Abstract][Full Text] [Related]
16. New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. Klemke CD; Goerdt S; Schrama D; Becker JC J Dtsch Dermatol Ges; 2006 May; 4(5):395-406. PubMed ID: 16686607 [TBL] [Abstract][Full Text] [Related]
17. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Jackson D; Stover D Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341 [TBL] [Abstract][Full Text] [Related]
18. Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. Zhu F; Zheng CJ; Han LY; Xie B; Jia J; Liu X; Tammi MT; Yang SY; Wei YQ; Chen YZ Curr Mol Pharmacol; 2008 Nov; 1(3):213-32. PubMed ID: 20021435 [TBL] [Abstract][Full Text] [Related]
19. Overview of targeted therapies in oncology. Kalyn R J Oncol Pharm Pract; 2007 Dec; 13(4):199-205. PubMed ID: 18045779 [TBL] [Abstract][Full Text] [Related]